Skip to main content

Table 1 Baseline characteristics of T2DM patients who were treated with SGLT2i (N = 151)

From: Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center

  Total patients (N = 151) DPP4i-treated patients (N = 108) Non DPP4i-treated patients (N = 43) p value
Age (years) 61.1 ± 12.2 60.7 ± 11.5 62.3 ± 14.1 0.473
Gender (% female) 79 (52.32%) 53 (48.18%) 26 (63.41%) 0.096
Duration of DM (years) 16.7 ± 9 16.3 ± 9 18 ± 9.1 0.297
Pre-treatment HbA1c (%NGSP) 8.8 ± 1.5 8.9 ± 1.4 8.4 ± 1.6 0.093
Baseline BW (kg) 78.2 ± 17.8 77.6 ± 18.7 79.8 ± 15.3 0.504
Baseline BMI (kg/m2) 29.8 ± 6 29.4 ± 6.1 31 ± 5.5 0.142
BMI categories (%)
 < 23.0 kg/m2 12 (7.95%) 10 (9.09%) 2 (4.88%) 0.395
 ≥ 23.0– < 25.0 kg/m2 17 (11.26%) 15 (13.64%) 2 (4.88%) 0.130
 ≥ 25.0– < 30.0 kg/m2 56 (37.09%) 42 (38.18%) 14 (34.15%) 0.648
 ≥ 30.0 kg/m2 66 (43.71%) 43 (39.09%) 23 (56.1%) 0.061
Diabetes treatment (%)
 No oral therapy 3 (1.99%) (0%) 3 (7.32%) 0.004
 1 oral therapy 10 (6.62%) 3 (2.73%) 7 (17.07%) 0.002
 2 oral therapy 30 (19.87%) 14 (12.73%) 16 (39.02%) < 0.001
 ≥ 3 oral therapy 108 (71.52%) 93 (84.55%) 15 (36.59%) < 0.001
Concomitant SU (%) 84 (55.63%) 64 (58.18%) 20 (48.78%) 0.301
Concomitant TZD (%) 74 (49.01%) 53 (48.18%) 21 (51.22%) 0.740
Insulin treatment 50 (33.11%) 33 (30%) 17 (41.46%) 0.183
Comorbid conditions (%)
 Ischemic heart disease 11 (7.28%) 8 (7.27%) 3 (7.32%) 0.765
 Congestive heart failure 3 (1.99%) 1 (0.91%) 2 (4.88%) 0.026
 Cerebrovascular disease 2 (1.32%) 2 (1.82%) 0 (0%) 0.565
Duration of SGLT2i (months) 17.8 ± 6.9 18.2 ± 6.7 16.9 ± 7.3 0.543